Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients

Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin’s lymphoma recently recognised as a distinct disease entity. Little is known about the prognostic factors and optimal treatment of MCL. The aim of this study was to analyse retrospectively the clinical features and effect of treatment in...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 1998-02, Vol.34 (3), p.329-336
Main Authors: Oinonen, R., Franssila, K., Teerenhovi, L., Lappalainen, K., Elonen, E.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Combined Modality Therapy
diagnosis
Female
Hematologic and hematopoietic diseases
Humans
International Prognostic Index
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Non-Hodgkin
Male
mantle cell lymphoma
Medical sciences
Middle Aged
Neoplasm Staging
non-Hodgkin’s lymphoma
prognosis
Remission Induction
Retrospective Studies
Survival Analysis
Survival Rate
treatment
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin’s lymphoma recently recognised as a distinct disease entity. Little is known about the prognostic factors and optimal treatment of MCL. The aim of this study was to analyse retrospectively the clinical features and effect of treatment in 94 MCL patients diagnosed and treated in one centre between 1980 and 1996, and to find out different factors influencing the treatment results and prognosis. The median age of the patients was 66 years, and 77% were over 60 years old. Of the patients, 76% had advanced disease, the performance status (PS) was WHO 0–1 in 86%, and B symptoms were present in 35% of the cases. Bone marrow infiltration was found in 61% and overt leukaemia in 12% of the patients. Of the patients, 47% achieved complete remission with first- or second-line therapy. The median duration of remission, time to treatment failure (TTF), and survival were 28, 18, and 41 months, respectively. In multivariate analyses, age, stage and leukaemic disease were significantly associated with TTF, and age, stage, leukaemic disease and lactate dehydrogenase (LDH) with survival. Long-term prognosis is poor in MCL. None of the conventional chemotherapies seems curative. A prospective randomised trial should be made to evaluate the benefit of anthracycline-containing regimens in MCL.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(97)10056-9